-
Mashup Score: 0Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis - 7 month(s) ago
Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T-cell (CAR-T) therapy is transforming the care of patients with relapsed/refractory multiple myeloma (MM). Unfortunately, despite being a disease of older adults these patients remain under-represented in most pivotal clinical trials. We performed a systematic review and proportion meta-analysis of prospective clinical trials and observational studies of anti-BCMA CAR-T therapy in patients with MM with the aim to determine the efficacy and safety of this therapy in older adults (≥65 years).
Source: www.geriatriconcology.netCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 02024 Tandem Meetings - 7 month(s) ago
ASTCT™ and CIBMTR® look forward to connecting with our international community of healthcare professionals at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® ,
Source: registration.tandemmeetings.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Abstract submissions to #Tandem24 are tonight! Don’t miss your chance to showcase your research to more than 5,000 members of the #HCT and #cellulartherapy field. Learn more: https://t.co/zztupzno2F #Tandem24 @CIBMTR https://t.co/TiXfqIzqXo
-
-
Mashup Score: 0Abstracts - 7 month(s) ago
Abstract submission deadline: October 9, 2023 Abstract accept/reject notification: December 1, 2023 Late breaking abstract submissions: December 4 – 18, 2023 Work submitted for presentation should not have been reported previously in an archival scientific publication, either as an article or as an abstract, at the time of submission. Data that has been, or will be, presented at any other meeting before being presented at the 2024 Tandem Meetings of ASTCT and CIBMTR, will not be accepted for presentation.
Source: registration.tandemmeetings.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Abstract submissions to #Tandem24 are due on Monday! Don’t miss your chance to showcase your research to more than 5,000 members of the #HCT and #cellulartherapy field. Learn more: https://t.co/zztupzno2F #Tandem24 @CIBMTR https://t.co/v1SXRRRg4t
-
-
Mashup Score: 0ASTCT Learning Center: 2023 ASTCT Clinical Immersion Course - 7 month(s) ago
The 2023 ASTCT Clinical Immersion Course took place virtually on Thursday, June 8 and Friday, June 9, 2023. This package includes access to the session recordings and slides. The Clinical Immersion Course provides an introductory overview to the field of hematopoietic cell transplantation (HCT) and cellular immunotherapy (CI). This course is ideal for industry stakeholders who are new to the field, as well as learners who seek to supplement their knowledge on the basics of HCT-CI. · Infectious Complications
Source: learn.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ASTCT’s Clinical Immersion Course is designed to provide a foundational knowledge base of #cellulartherapy and #HCT for industry partners. Recordings and slides from the June course are now available for purchase: https://t.co/zJxNX7q9Qa https://t.co/dVqYkGmJci
-
-
Mashup Score: 0The Breakthrough Battle Against Metastatic Melanoma: Unleashing TIL Therapy's Trailblazing Potential - 9 month(s) ago
Metastatic melanoma is an aggressive form of skin cancer that poses significant challenges in treatment and prognosis. Despite advances in targeted therapies and immunotherapies, patients with metastatic melanoma often face limited treatment options and poor survival rates. Almost 50% of patients are still not responding to the latest approved immunotherapies. However, recent breakthroughs in Tumor-Infiltrating Lymphocyte (TIL) therapy have sparked hope in the medical community.
Source: doc4heart.substack.comCategories: Cardiologists, Latest HeadlinesTweet-
The Breakthrough Battle Against Metastatic Melanoma: Unleashing TIL Therapy's Trailblazing Potential , by @Doc4Heart https://t.co/gt4nwgSFPy #substack #melanoma #metastaticmelanoma #cellulartherapy #Immunotherapy
-
-
Mashup Score: 8ASTCT > Attend > ASTCT + EBMT Relapse Conference - 9 month(s) ago
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field.
Source: www.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Don't miss your chance to make an impact among #HCT & #cellulartherapy researchers — the submission deadline for #RelapseConference23 abstracts has been extended to Sept. 8! Showcase your relapse post-transplant-related findings this fall: https://t.co/oj199sbbTU @TheEBMT https://t.co/OYLXmf78Tr
-
-
Mashup Score: 3ASTCT > Attend > ASTCT/EBMT 6th International Conference - 9 month(s) ago
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field.
Source: www.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 Attention all researchers in #HCT & #cellulartherapy! The deadline to submit an abstract for #RelapseConference23 has been extended to Sept. 8. Take advantage of this opportunity to showcase your findings related to relapse post-transplant: https://t.co/oj199sbbTU @TheEBMT https://t.co/vnpmXhfwd6
-
-
Mashup Score: 0ASTCT > Attend > Event Calendar - 10 month(s) ago
The American Society for Transplantation and Cellular Therapy is an international professional membership association of more than 3,600 physicians, investigators and other health care professionals from more than 45 countries. Our mission is dedicated to improving the application and success of blood and marrow transplantation and related cellular therapies. We strive to be the leading organization promoting research, education and clinical practice in the field.
Source: www.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The ASTCT + @TheEBMT #RelapseConference23 will cover the mechanisms of relapse, relapse prevention and treatment of relapse in the field of #HSCT and #cellulartherapy. Register to attend: https://t.co/cN5Dvlr8Q9 https://t.co/SyL1bVzKVQ
-
-
Mashup Score: 0- ASTCT - 10 month(s) ago
Skip to main content (Press Enter). Sign In Skip auxiliary navigation (Press…
Source: www.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The CAR-T Cell Therapy Coding and Billing Guide is designed to help providers understand billing considerations for CAR-T diagnosis, procedures and product coding. With quarterly updates, this guide will become a go-to resource: https://t.co/RJKeBt3XZs #CARTcells #cellulartherapy https://t.co/PBABoxH3lc
-
-
Mashup Score: 0Coverage, Coding, Billing and Reimbursement - ASTCT - 10 month(s) ago
Looking for ASTCT Comment Letters? ASTCT regularly issues policy statements on a wide range of topics regarding bone marrow transplantation and cellular therapy. Click here to view letters on a wide range of topics. Webinars and Other Presentations Please note: users must be logged in to access recordings in the ASTCT Learning Center. If you are not an ASTCT member, you can create a guest…
Source: www.astct.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Coding and reimbursement is a complicated—yet essential—part of the cellular therapy field. Updated CAR-T billing and coding grids are now available to the entire #HCT and #cellulartherapy community to download for free on the ASTCT website: https://t.co/WEWR0fBRuL https://t.co/rvjC4AndGj
-
Safety and efficacy of anti-BCMA CAR-T cell therapy in older adults with multiple myeloma: A systematic review and meta-analysis https://t.co/fO900h0XcF @WilliamDale_MD @rochgerionc @myCARG #GeriOnc #OlderAdults #OncoAlert #SIOG #YoungSIOG #CellularTherapy #CARTTherapy https://t.co/pineBpKNy2